Keyword search (4,163 papers available)

"Borges C" Authored Publications:

Title Authors PubMed ID
1 The Role of the Posterior Paraventricular Nucleus of the Thalamus in Food Deprivation-Induced Heroin-Seeking Relapse, in Male and Female Rats Borges C; Darecka A; Mainville-Berthiaume A; Ah-Yen E; Darvishmolla M; Courtemanche R; Shalev U; 41506524
HKAP
2 Acute food deprivation-induced relapse to heroin seeking after short and long punishment-imposed abstinence in male rats Borges C; Inigo F; Quteishat N; Charles J; Ah-Yen E; U S; 35951079
CSBN
3 The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats Iriah SC; Borges C; Shalev U; Cai X; Madularu D; Kulkarni PP; Ferris CF; 34625487
CONCORDIA

 

Title:The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats
Authors:Iriah SCBorges CShalev UCai XMadularu DKulkarni PPFerris CF
Link:pubmed.ncbi.nlm.nih.gov/34625487/
DOI:10.1503/jpn.200191
Publication:Journal of psychiatry & neuroscience : JPN
Keywords:
PMID:34625487 Category: Date Added:2021-10-09
Dept Affiliation: CONCORDIA
1 From the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev). s.iriah@northeastern.edu.
2 From the Centre for Translational Neuroimaging, Northeastern University, Boson, Mass., USA (Iriah, Cai, Madularu, Kulkarni, Ferris); and Concordia University, Montreal, Que., Canada (Borges, Shalev).

Description:

Background: Maraviroc is an antiretroviral agent and C-C chemokine coreceptor 5 (CCR5) antagonist that is currently used to treat human immunodeficiency virus. CCR5/ยต-opioid receptor heterodimerization suggests that maraviroc could be a treatment for oxycodone abuse. We treated rats with maraviroc to explore its effect on oxycodone-seeking and its interference with the analgesic effects of oxycodone. We used resting-state blood-oxygen-level-dependent functional connectivity to assess the effect of maraviroc on oxycodone-enhanced coupling in the reward circuitry and performed behavioural tests to evaluate the effect of maraviroc on oxycodone rewarding properties and on oxycodone-seeking after prolonged abstinence.

Methods: Two groups of rats were exposed to 8 consecutive days of oxycodone-conditioned place preference training and treatment with maraviroc or vehicle. Two additional groups were trained to self-administer oxycodone for 10 days and then tested for drug seeking after 14 days of abstinence with or without daily maraviroc treatment. We tested the effects of maraviroc on oxycodone analgesia using a tail-flick assay. We analyzed resting-state functional connectivity data using a rat 3-dimensional MRI atlas of 171 brain areas.

Results: Maraviroc significantly decreased conditioned place preference and attenuated oxycodone-seeking behaviour after prolonged abstinence. The analgesic effect of oxycodone was maintained after maraviroc treatment. Oxycodone increased functional coupling with the accumbens, ventral pallidum and olfactory tubercles, but this was reduced with maraviroc treatment.

Limitations: All experiments were performed in male rats only.

Conclusion: Maraviroc treatment attenuated oxycodone-seeking in abstinent rats and reduced functional coupling in the reward circuitry. The analgesic effects of oxycodone were not affected by maraviroc.




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University